![](../_images/band-covid19.jpg)
NANT 001 and NANT XL Systems installed in the Facility of ImmunityBio (Culver City, CA) for the scale-out production of an allogeneic Mesenchymal Stem Cell (MSC) therapy to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.
Scale Out is a Choice
![](../_images/chunk-icon-scaleout-transition.png)
Easy Transition from the Traditional Manual Process
NANT Systems support the scale-out of cell therapy manufacturing, allowing an easier optimization of the cell expansion protocol with a reduced cell culture volume, and giving the opportunity to adjust the capacity of your facility according to the demand.
![](../_images/chunk-icon-scaleout-contamination.png)
Avoiding Cross-Contamination Risks
Cross-contamination is avoided thanks to our fully closed cGMP-compliant Systems, designed to ensure the aseptic processing and cell culture expansion.
![](../_images/chunk-icon-scaleout-multiproduct.png)
Supporting a Wide Range of ATMP Products
NANT Systems can support the production of different cell therapy processes at the same time in the same place, allowing the manufacturing of multi-product ATMPs. §4.2 and §9.4 of the Guidelines on GMP specific to ATMPs – EudraLex Vol.4 /GMP (2018)